Press Releases

Launch of the EHVA consortia funded by the EU H2020 program

27 January 2016

The European HIV Vaccine Alliance (EHVA) is a project funded by EU H2020 program. Its primary objective is to develop a multidisciplinary platform to evaluate novel preventive and therapeutic vaccines. EuroVacc provides the support in the scientific project management.

English French

Start of the EV02 trial in Lausanne and London

16 February 2005

EuroVacc started the phase I trial (EV02) in Lausanne and London to evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection.

English French German

Results from EV01 trial in Lausanne and London

7 June 2004

The results from the EV01 trial, to evaluate and safety and immunogenicity of NYVAC-C, showed that the vaccine is well tolerated and vaccine-induced T-cell responses were observed in 45% of the vaccine recipients.

English French

Start of the EV01 trial in Lausanne and London

30 July 2003

EuroVacc started the phase I trial (EV01) in Lausanne and London to evaluate the safety and immunogenicity of NYVAC-C. 

English French